Fondazione del Piemonte per I Oncologia IRCC Candiolo

Candiolo 10060

1 studies enrolling now · 2 studies all time

What they study most

Colorectal Neoplasms, Urinary Bladder Neoplasms

Studies at this site

• A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy — Recruiting now
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Running, not enrolling